(13) Table 1 includes a summary of the incidence rate and median time to onset of CRS observed in the respective registrational clinical trial for each of the commercially available anti-CD19 and anti-BCMA CAR T cell therapies. The gene discussed is TNFRSF17; the disease is congenital rubella syndrome.